Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Alnodesertib

Source date not recordedAnalyse record ↗

ATR kinase inhibitor in a recruiting Phase 1/2a solid-tumor study.

Modality
oral small-molecule ATR kinase inhibitor
Availability (US)
Phase 1/2a STELLA study Recruiting
Biomarkers
dose-limiting toxicities; adverse events; pharmacokinetics; RECIST response; progression-free survival
Hallmark targeted
genomic instability, DNA-damage response, replication stress
Kind
investigational drug
Clinical trials
NCT04657068 — Phase 1/Phase 2, Recruiting on July 30, 2026 update